Group 1 - The core point of the announcement is that Guangdong Hengjian International Investment Co., Ltd., a shareholder holding more than 5% of the shares, has completed its share reduction plan without executing any sales during the designated period [1] - As of the announcement date, Hengjian International holds 33,123,600 shares of Dirui Medical Technology Co., Ltd., representing 12.15% of the company's total share capital [1] - The share reduction plan complies with various relevant laws and regulations, including the Company Law of the People's Republic of China and the Securities Law of the People's Republic of China [1]

证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-039 迪瑞医疗科技股份有限公司 关于持股 5%以上股东减持股份计划实施期限届满的公告 持股 5%以上的股东广东恒健国际投资有限公司保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 截至本公告披露日，恒健国际本次减持计划实施期限已届满，本次减持计划 期间内未减持其持有的公司股份。恒健国际持有公司股份数量为 33,123,600 股， 占公司目前总股本比例为 12.15%。 二、其他相关说明 1、恒健国际本次减持计划符合《中华人民共和国公司法》《中华人民共和国 证券法》《上市公司收购管理办法》《深圳证券交易所创业板股票上市规则》《上 市公司股东减持股份管理暂行办法》《深圳证券交易所上市公司自律监管指引第 18 号——股东及董事、高级管理人员减持股份》等法律、法规及规范性文件的 规定。 2、上述股东本次减持公司股份事项已按照相关规定进行了预披露，本次减 持符合已披露的减持计划，本次减持计划期间未减持公司股份，不存在违规情形。 截至目前，本次减持计划实施期限已届满。 三、备查文件 恒健国际出具的《关于减持迪瑞医疗股份计 ...

Group 1: Financial Performance - The company experienced a loss in the first half of 2025 due to multiple factors including macroeconomic slowdown, ongoing procurement policies, and intensified industry competition [2] - Total expenses for sales, management, and R&D decreased by 16% year-on-year, enhancing operational efficiency [5] - Cash flow increased by 97.07% year-on-year, indicating improved financial health [6] Group 2: International Market Strategy - The international business grew by 24% year-on-year, with significant growth in key markets such as India, Asia-Pacific, and Turkey [3] - The company has over 20 years of experience in overseas operations, focusing on local management to enhance brand value [3] Group 3: Strategic Adjustments - A new management team with industry backgrounds is conducting a strategic review to enhance the company's operational effectiveness [4] - The company aims to focus on three core areas in the second half of 2025: expanding international markets, accelerating domestic equipment installation, and optimizing the supply chain [2] Group 4: R&D and Technological Advancements - The company launched a fully automated urine analyzer, achieving high precision in identifying 50 types of cells [6] - Progress in AI integration within medical technology is being pursued, with advancements in intelligent recognition systems for medical imaging [7] Group 5: Cost Management - Financial expenses saw a significant reduction due to improved fund management and currency risk control, with interest income increasing by approximately 1.391 million [6] - The company implemented precise resource allocation in marketing, leading to enhanced cost efficiency [5]

Core Insights - The company, Dirui Medical, reported a significant decline in financial performance for the first half of 2025, with total revenue of 351 million yuan, a year-on-year decrease of 60.07% [1] - The net profit attributable to shareholders was -28.31 million yuan, reflecting a year-on-year decline of 117.13% [1] - The company's gross margin decreased to 38.85%, down 9.85% year-on-year, while the net margin turned negative at -8.07%, a drop of 142.92% [1] Financial Performance Summary - Total revenue for 2025 was 351 million yuan, down from 878 million yuan in 2024, a decrease of 60.07% [1] - Net profit attributable to shareholders was -28.31 million yuan, compared to a profit of 16.5 million yuan in 2024, a decline of 117.13% [1] - The company's operating expenses, including financial, sales, and administrative costs, accounted for 30.61% of total revenue, an increase of 83.13% year-on-year [1] - The gross margin was 38.85%, down from 43.10% in 2024, a decrease of 9.85% [1] - The net margin was -8.07%, compared to 18.81% in 2024, a decline of 142.92% [1] Cash Flow and Debt Analysis - The net cash flow from operating activities showed a significant improvement, with a change of 97.07% due to better sales collection compared to the previous year [3] - The company’s interest-bearing debt increased to 550 million yuan, a rise of 70.00% from 324 million yuan in 2024 [1] - The net increase in cash and cash equivalents was up by 77.99%, influenced by the net cash flow from operating activities [4] Business Model and Market Strategy - The company relies heavily on research and development as well as marketing to drive its performance [4] - In the first quarter of 2025, the company focused on enhancing the installation of instruments and increasing reagent sales in the domestic market, completing over 400 instrument installations [4] - The international market strategy has been adjusted to focus on Southeast Asia and key countries along the Belt and Road Initiative, with minimal impact from uncontrollable factors [4]

Core Points - The company did not distribute cash dividends or issue bonus shares during the reporting period [3] - There were no changes in the controlling shareholder or actual controller during the reporting period [5] - The company held two board meetings and a shareholder meeting in July and August 2025, resulting in changes to the board of directors and management [5] Company Overview - The company is named Dirui Medical Technology Co., Ltd. and is listed under the stock code 300396 [6] - The half-year report was disclosed on August 26, 2025, on the designated information disclosure website [6] Financial Data - The report includes key accounting data and financial indicators, although specific figures are not provided in the excerpts [4]

Core Viewpoint - DIRUI Medical Technology Co., Ltd. reported a significant decline in revenue and net profit for the first half of 2025, indicating challenges in the medical device industry, particularly in the in vitro diagnostics (IVD) sector, amidst increasing competition and regulatory pressures [4][6]. Company Overview and Financial Indicators - The company’s stock code is 300396, and it is listed on the Shenzhen Stock Exchange [4]. - For the reporting period, the company generated revenue of approximately ¥350.69 million, a decrease of 60.07% compared to the same period in 2024 [4]. - The net profit attributable to shareholders was a loss of approximately ¥28.31 million, a decline of 117.13% year-on-year [4]. - The company plans not to distribute cash dividends or issue bonus shares [4]. Industry Analysis - The medical device industry, particularly the IVD sector, is experiencing a transformation driven by AI technology and increasing domestic demand [6]. - The IVD market in China is projected to grow to ¥288.15 billion by 2030, capturing 33.2% of the global market share [6]. - The industry is facing challenges due to macroeconomic conditions, healthcare cost control, and intensified centralized procurement, which may slow overall growth in 2024 [6]. Business Operations - The company focuses on the research, production, marketing, and service of medical testing instruments and related reagents, covering a wide range of diagnostic applications [6][10]. - DIRUI Medical employs a sales model that emphasizes distribution partnerships while also engaging in direct sales [10]. - The company has made significant investments in R&D, aiming to enhance product quality and expand its market presence both domestically and internationally [10]. Regulatory Environment - Recent government policies aim to support the medical device sector through measures such as large-scale equipment updates and the establishment of a unified national market for medical devices [5]. - The company has obtained numerous medical device registrations and certifications, including 414 medical device registration certificates and 483 CE certifications [12]. Market Trends - The IVD sector is expected to benefit from policies promoting domestic production and innovation, which may help local companies gain market share against international competitors [6]. - The trend towards centralized procurement and cost control in hospitals is pushing companies to optimize their cost structures and improve product differentiation [6]. Product Portfolio - DIRUI Medical's product lines include urine analysis, biochemical analysis, immunoassay, and coagulation analysis, among others, covering over 80% of testing items in clinical laboratories [10]. - The company’s products are designed to provide critical diagnostic information for disease prevention and treatment [10].

Core Viewpoint - The report indicates a significant decline in the company's financial performance for the first half of 2025, with a notable drop in revenue and net profit compared to the same period last year [2][3]. Financial Performance - The company's operating revenue for the reporting period was approximately ¥350.69 million, representing a decrease of 60.07% compared to ¥878.27 million in the same period last year [2]. - The net profit attributable to shareholders was a loss of approximately ¥28.31 million, a decline of 117.13% from a profit of ¥165.24 million in the previous year [2]. - The net profit after deducting non-recurring gains and losses was approximately -¥31.91 million, down 119.65% from ¥162.36 million in the previous year [2]. - The net cash flow from operating activities was approximately -¥8.43 million, showing an improvement of 97.07% compared to -¥287.72 million in the previous year [2]. - Basic and diluted earnings per share were both -¥0.1038, a decrease of 117.13% from ¥0.6060 in the previous year [2]. - The weighted average return on net assets was -9.28%, down from 7.88% in the previous year [2]. Asset and Equity Position - Total assets at the end of the reporting period were approximately ¥2.96 billion, a decrease of 4.71% from ¥3.11 billion at the end of the previous year [2]. - The net assets attributable to shareholders were approximately ¥1.96 billion, down 4.51% from ¥2.05 billion at the end of the previous year [3]. Shareholder Information - The largest shareholder, Shenzhen Huadexin Run Equity Investment Co., Ltd., holds 28.34% of the shares, with a total of 77,288,400 shares [3]. - Other significant shareholders include Guangdong Hengjian International Investment Co., Ltd. with 12.15% and individual shareholders such as Song Jie and Yi Xiangping with 5.40% and 3.21% respectively [3][4]. - The report notes that there have been no changes in the controlling shareholder or actual controller during the reporting period [4]. Important Events - Several directors, including Song Qing, Qin Feng, Wang Xueming, and Lin Maoliang, have resigned from their positions, and new non-independent directors have been elected [4]. - Sun Bin has been appointed as the vice general manager of the company [4].

Core Viewpoint - The report indicates a significant decline in revenue and net profit for the first half of 2025, while the international market shows resilience with a 20% increase in revenue compared to the previous year [1][2]. Group 1: Financial Performance - The company's operating revenue for the first half of 2025 was 351 million yuan, representing a year-on-year decrease of 60.07% [1]. - The net profit attributable to shareholders was a loss of 28.31 million yuan, reflecting a year-on-year decline of 117.13% [1]. Group 2: International Market Strategy - The company has implemented a dual-drive strategy focusing on both domestic and international markets, with ongoing efforts in local management and product upgrades [1]. - The international market has shown stability, with revenue growth in countries like India, the Philippines, and Turkey, and several high-speed models have received registration in various countries [1][2]. - The company has shifted from a "multi-point layout" to a "refined cultivation" strategy in the international market, concentrating resources on twelve key countries to enhance competitive strength [2]. Group 3: Product Development and Market Presence - The company has achieved registration for several key products, including biochemical and urine testing instruments, which are now being marketed internationally [1]. - The company’s seven major product series are sold in over 120 countries and regions, establishing stable sales channels and brand influence [2].

Group 1 - The core viewpoint of the article is that Diri Medical (300396.SZ) reported a significant decline in revenue and net profit for the first half of 2025, indicating financial challenges [1] Group 2 - The company achieved operating revenue of 351 million yuan in the first half of 2025, representing a year-on-year decrease of 60.07% [1] - The net profit attributable to shareholders of the listed company was -28.31 million yuan, marking a shift from profit to loss compared to the previous year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -31.91 million yuan [1] - The basic earnings per share were -0.1038 yuan [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）《2025 年半年度报告》 及其摘要于 2025 年 8 月 26 日在中国证监会指定的创业板信息披露网站上披露。 为便于投资者进一步了解公司的生产经营等情况，公司拟定于 2025 年 8 月 26 日（星期二）15：30 至 17：00 采取网络远程的方式举办 2025 年半年度报告网 上业绩说明会。 投资者参与本次业绩说明会具体方式如下： 1、时间：2025 年 8 月 26 日（星期二）15：30 至 17：00； 证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-037 2、参与方式：投资者可登陆全景网"投资者关系互动平台"（https://ir.p5w.net） 参与本次业绩说明会。 迪瑞医疗科技股份有限公司 出席本次网上业绩说明会的人员有：公司副总经理、财务总监张兴艳女士， 董事、副总经理、董事会秘书安国柱先生（如有特殊情况，参与人员会有调整）。 关于举行 2025 年半年度报告网上业绩说明会的公告 欢迎广大投资者积极参与。 特此公告。 迪瑞医 ...